Reneo Pharmaceuticals Inc (RPHM)
1.75
+0.02
(+1.16%)
USD |
NASDAQ |
May 03, 16:00
1.75
0.00 (0.00%)
After-Hours: 20:00
Reneo Pharmaceuticals Cash from Financing (TTM): 60.86M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 60.86M |
September 30, 2023 | 65.32M |
June 30, 2023 | 65.24M |
March 31, 2023 | 1.474M |
December 31, 2022 | 0.471M |
September 30, 2022 | 0.265M |
June 30, 2022 | 0.39M |
Date | Value |
---|---|
March 31, 2022 | 86.19M |
December 31, 2021 | 132.41M |
September 30, 2021 | 179.48M |
June 30, 2021 | 179.31M |
March 31, 2021 | 93.47M |
December 31, 2020 | 47.27M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.265M
Minimum
Sep 2022
179.48M
Maximum
Sep 2021
70.17M
Average
65.24M
Median
Jun 2023
Cash from Financing (TTM) Benchmarks
Mirum Pharmaceuticals Inc | 336.60M |
NovaBay Pharmaceuticals Inc | 1.91M |
Palatin Technologies Inc | 5.553M |
iBio Inc | 10.68M |
Theriva Biologics Inc | 0.625M |